Stadio Holdings vs Fredun Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how Stadio Holdings (SDO) and Fredun Pharmaceuticals (FREDUN) compare, as of Aug 11, 2026.
As of Aug 11, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the more attractively valued of the two: Stadio Holdings trades at ZAR 12.85 versus a fair value of ZAR 7.57 (-41%), while Fredun Pharmaceuticals trades at ₹1,218 versus ₹2,019 (+66%).
Stadio Holdings
SDO.JSE · ZAR · Consumer Discretionary
-41%
upside to fair value
overvalued
PriceZAR 12.85
Fair ValueZAR 7.57
Quality68/100
Fredun Pharmaceuticals
FREDUN.BSE · INR · Healthcare
+66%
upside to fair value
undervalued
Price₹1,218
Fair Value₹2,019
Quality33/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Stadio HoldingsFredun Pharmaceuticals
Valuation
33.8×P/E (TTM)42.2×
5.90×P/S (TTM)2.23×
5.23×P/B5.03×
21.3×EV/EBITDA15.5×
0.0%Dividend yield0.0%
ZAR 0.18Dividend per share₹0.70
Profitability
18%Net margin5%
24%Operating margin12%
16%Return on equity16%
11%Return on assets9%
Growth
13%Revenue growth (YoY)27%
14.9%Avg. growth/yr (3Y)32.2%
14.6%Avg. growth/yr (5Y)36.9%
Balance & size
—Debt / equity0.20×
$671MMarket cap$149M
mixedGrowth qualityexpensive
Fredun Pharmaceuticals leads: 5 to 7 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Stadio Holdingsof which business quality 65 · market factors 74Fredun Pharmaceuticalsof which business quality 35 · market factors 44
ProfitabilityMargins and returns on capital today
63
48
Quality GrowthAre margins and returns improving?
60
73
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
58
16
Low VolatilityCalm price path (market factor)
77
43
MomentumPrice trend over the last 3–12 months (market factor)
65
39
52W MomentumDistance to the 52-week high (market factor)
85
54
Net IssuanceBuybacks instead of dilution
80
7
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Stadio Holdings
DCF ModelsZAR 8.03
Earnings-BasedZAR 12.80
Dividend DiscountZAR 2.68
MultiplesZAR 7.23
Asset-BasedZAR 1.65
Growth DCFZAR 5.47
Economic ProfitZAR 5.50
Growth EarningsZAR 17.18
22 of 26 models see the stock below the current price.
Fredun Pharmaceuticals
Earnings-Based₹1,942
Multiples₹1,723
Asset-Based₹345
Economic Profit₹1,854
Growth Earnings₹2,535
5 of 14 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Stadio Holdings
Bear ZAR 5.35Fair Value ZAR 7.57Bull ZAR 13.06
ZAR 12.85 = current price (white tick)
Fredun Pharmaceuticals
Bear ₹1,379Fair Value ₹2,019Bull ₹2,712
₹1,218 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Stadio Holdings · Consumer Discretionary
Quality score68 · Top 25%
Fair value upside-41% · below median
Fredun Pharmaceuticals · Healthcare
Quality score33 · bottom 25%
Fair value upside+66% · Top 25%
Bottom line
As of Aug 11, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the more attractively valued of the two: Stadio Holdings trades at ZAR 12.85 versus a fair value of ZAR 7.57 (-41%), while Fredun Pharmaceuticals trades at ₹1,218 versus ₹2,019 (+66%).
Stadio Holdings has the higher quality score (68/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
